Kluwer Patent Blog

United Kingdom: GSK v Wyeth, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2015-000002, 12 May 2016

Claire Phipps-Jones (Bristows) · Thursday, March 9th, 2017

The UK Patents Court upheld the validity of Wyeth's patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK's allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called "AgrEvo" obviousness), insufficiency and added matter. The court also held that a number of the claims were infringed by GSK's meningitis B vaccine, Bexsero.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



The Wolters Kluwer Future Ready Lawyer

Leading change

📆 Wolters Kluwer

This entry was posted on Thursday, March 9th, 2017 at 11:51 am and is filed under Case Law, United Kingdom

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.